Publications
Detailed Information
The Chemokine Receptor CCR4 is Expressed and Associated With a Poor Prognosis in Patients With Gastric Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jun Ho | - |
dc.contributor.author | Cho, Young-Suk | - |
dc.contributor.author | Lee, Ji Young | - |
dc.contributor.author | Kook, Myoung Cheorl | - |
dc.contributor.author | Nam, Byung-Ho | - |
dc.contributor.author | Bae, Jae-Moon | - |
dc.contributor.author | Park, Jong-Whan | - |
dc.date.accessioned | 2012-07-02T08:43:15Z | - |
dc.date.available | 2012-07-02T08:43:15Z | - |
dc.date.issued | 2009-06 | - |
dc.identifier.citation | ANNALS OF SURGERY; Vol.249 6; 933-941 | ko_KR |
dc.identifier.issn | 0003-4932 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78131 | - |
dc.description.abstract | Objectives: There is increasing evidence that chemokines and chemokine receptors are causally involved in the metastasis of cancer. Little is known about the possible role of chemokine receptors in the metastasis of gastric cancer. The aim of this study was to investigate the expression of chemokine receptors and their prognostic role in patients with gastric cancer. Methods: We screened the expression or CCR and CXCR chemokine receptors in 12 gastric cancer cell lines using the semi-quantitative RT-PCR. The expression of CCR4, one of the most commonly expressed chemokines, was confirmed using Western blot and flow cytometry analysis of 8 gastric cancer cell lines. The function of CCR4 was examined using migration and proliferation assays. Then the migratory response of CCR4 was blocked using blocking antibodies. Finally, the clinical significance of the chemokine receptors was explored using tissue microarray methods and immunohistochemical staining of specimens front 753 gastric cancer patients. Results: We found that 6 out of 8 (75.0%) gastric carcinoma cell lines expressed a functional CCR4 for its ligand, chemokine CCL17, as demonstrated by the migration assays, and the migration was inhibited by anti-CCR4 antibodies. The clinical samples evaluated by immunohistochemical and chemical assay of tissue microarrays showed that CCR4-positive carcinoma cells were detected in 128 of 753 (17.0%) cases. In addition, there was a significant difference in recurrences between the CCR4-positive and -negative cases (P = 0.009). The patients with CCR4-positive tumors had significantly poorer Prognosis than did those with CCR4-negative tumors (5-year Survival rate; 71.6% versus 82.5%; respectively, P = 0.008). Conclusion: These results suggest that CCR4 and its ligands were associated with increased tumor recurrence and impaired overall survival ill patients with gastric cancer. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | ko_KR |
dc.subject | Gastric cancer | ko_KR |
dc.subject | metastasis | ko_KR |
dc.subject | chemokine | ko_KR |
dc.title | The Chemokine Receptor CCR4 is Expressed and Associated With a Poor Prognosis in Patients With Gastric Cancer | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이준호 | - |
dc.contributor.AlternativeAuthor | 조영석 | - |
dc.contributor.AlternativeAuthor | 이지영 | - |
dc.contributor.AlternativeAuthor | 국명철 | - |
dc.contributor.AlternativeAuthor | 박종환 | - |
dc.contributor.AlternativeAuthor | 남병호 | - |
dc.contributor.AlternativeAuthor | 배재문 | - |
dc.identifier.doi | 10.1097/SLA.0b013e3181a77ccc | - |
dc.citation.journaltitle | ANNALS OF SURGERY | - |
dc.description.citedreference | Kim EJ, 2007, J CLIN INVEST, V117, P836, DOI 10.1172/JCI24826C1 | - |
dc.description.citedreference | Ghadjar P, 2006, J CLIN ONCOL, V24, P1910, DOI 10.1200/JCO.2005.04.1822 | - |
dc.description.citedreference | Yasumoto K, 2006, CANCER RES, V66, P2181, DOI 10.1158/0008-5472.CAN-05-3393 | - |
dc.description.citedreference | Azuma H, 2005, J NATL CANCER I, V97, P1734, DOI 10.1093/jnci/dji399 | - |
dc.description.citedreference | Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385 | - |
dc.description.citedreference | Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389 | - |
dc.description.citedreference | Ishida T, 2004, CLIN CANCER RES, V10, P7529 | - |
dc.description.citedreference | Chun JH, 2004, CANCER RES, V64, P4703 | - |
dc.description.citedreference | Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370 | - |
dc.description.citedreference | Marrelli D, 2004, J AM COLL SURGEONS, V198, P51, DOI 10.1016/j.jamcollsurg.2003.08.013 | - |
dc.description.citedreference | Kodera Y, 2003, ANN SURG ONCOL, V10, P898, DOI 10.1245/ASO.2003.12.009 | - |
dc.description.citedreference | Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874 | - |
dc.description.citedreference | Dellacasagrande J, 2003, SCAND J IMMUNOL, V57, P534 | - |
dc.description.citedreference | Udayakumar TS, 2003, CANCER RES, V63, P2292 | - |
dc.description.citedreference | Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008 | - |
dc.description.citedreference | Mashino K, 2002, CANCER RES, V62, P2937 | - |
dc.description.citedreference | Ghia P, 2002, EUR J IMMUNOL, V32, P1403 | - |
dc.description.citedreference | Ohshima K, 2002, INT J CANCER, V98, P567, DOI 10.1002/ijc.10218 | - |
dc.description.citedreference | Yoshie O, 2002, BLOOD, V99, P1505 | - |
dc.description.citedreference | SHIN HR, 2002, CANC RES TREAT, V34, P405 | - |
dc.description.citedreference | Macdonald JS, 2001, NEW ENGL J MED, V345, P725 | - |
dc.description.citedreference | Yonemura Y, 2001, CLIN CANCER RES, V7, P1647 | - |
dc.description.citedreference | Muller A, 2001, NATURE, V410, P50 | - |
dc.description.citedreference | SOKOBE M, 2001, NAT MED, V7, P192 | - |
dc.description.citedreference | Constantin G, 2000, IMMUNITY, V13, P759 | - |
dc.description.citedreference | Yoo CH, 2000, BRIT J SURG, V87, P236 | - |
dc.description.citedreference | Zlotnik A, 2000, IMMUNITY, V12, P121 | - |
dc.description.citedreference | McGrath KE, 1999, DEV BIOL, V213, P442 | - |
dc.description.citedreference | Kim JP, 1999, SEMIN SURG ONCOL, V17, P132 | - |
dc.description.citedreference | van den Berg A, 1999, AM J PATHOL, V154, P1685 | - |
dc.description.citedreference | Muller W, 1998, CANCER, V83, P2481 | - |
dc.description.citedreference | Siewert JR, 1998, ANN SURG, V228, P449 | - |
dc.description.citedreference | Andrew DP, 1998, EUR J IMMUNOL, V28, P1959 | - |
dc.description.citedreference | Su SB, 1997, BLOOD, V90, P605 | - |
dc.description.citedreference | Mori M, 1997, INT J CANCER, V74, P316 | - |
dc.description.citedreference | Mori M, 1997, NAT MED, V3, P593 | - |
dc.description.citedreference | Jawhari A, 1997, GASTROENTEROLOGY, V112, P46 | - |
dc.description.citedreference | Bao LR, 1996, NAT MED, V2, P1322 | - |
dc.description.citedreference | Mitchison TJ, 1996, CELL, V84, P371 | - |
dc.description.citedreference | FOSTER SJ, 1989, IMMUNOLOGY, V67, P181 | - |
dc.description.citedreference | MCCARTHY JB, 1986, J CELL BIOL, V102, P179 | - |
dc.description.citedreference | NICOLSON GL, 1978, CANCER RES, V38, P4105 | - |
dc.description.tc | 4 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.